Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1996, for OXIS International, Inc. (Note: The request metadata listed "GT Biopharma, Inc.", but the filing text identifies the registrant as OXIS International, Inc.). The company operates in the biotechnology sector, focusing on diagnostic assays, bovine superoxide dismutase (bSOD), and therapeutic development. The financial statements are prepared on a going concern basis, though management notes significant doubt regarding the company's ability to continue as a going concern without additional financing.
Key Financial Metrics
| Metric | Q1 1996 | Q1 1995 |
|---|---|---|
| Total Revenues | $1,367,000 | $2,126,000 |
| Net Loss | $(1,546,000) | $(757,000) |
| Net Loss Per Share | $(0.13) | $(0.08) |
| Cash and Cash Equivalents (End of Period) | $875,000 | $724,000 |
| Working Capital Deficit | $(1,956,000) | $(1,469,000) |
| Total Debt (Notes Payable + Capital Leases + Debentures) | $3,374,000 | N/A |
| Operating Cash Flow | $(541,000) | $(899,000) |
Liquidity: Current liabilities ($4,681,000) exceed current assets ($2,725,000). The company raised $784,000 in stock proceeds during the quarter and an additional $600,000 subsequent to the period end.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 36% to $1.367 million. Product sales dropped from $2.075 million to $1.337 million, primarily due to a $500,000 decrease in bulk bSOD sales following the cessation of a major contract with Sanofi Winthrop Inc.
- Widening Losses: Net loss more than doubled to $1.546 million. This was driven by reduced gross margins (cost of sales rose to 69% of product sales from 57%) and increased operating expenses.
- Expense Increases: Research and development (R&D) expenses rose 15% to $1.182 million due to the integration of Therox Pharmaceuticals and preclinical testing. Selling, general, and administrative (SG&A) expenses increased 16% to $745,000, driven by equity financing costs and foreign exchange losses.
- Working Capital: The working capital deficit widened by $487,000 to $1.956 million, despite cash inflows from equity issuance.
Outlook, Risks, and Management Commentary
- Capital Needs: Management explicitly states the company must raise additional capital during the first half of 1996 to continue operations. Failure to do so would result in severe curtailment or cessation of operations.
- Revenue Uncertainty: Future sales of bulk bSOD are uncertain as the Sanofi Winthrop contract has ended. The company is dependent on developing business alliances to commercialize new technologies.
- Going Concern: The filing includes a "going concern" warning. The company has incurred losses for three consecutive years and relies on private placements of Series C Preferred Stock to fund operations.
- Recent Financing: Subsequent to March 31, 1996, the company raised an additional $600,000 via private placement. Through May 13, 1996, total proceeds from Series C Preferred Stock sales reached $1.463 million.
Investor Verification Checklist
- Capital Sufficiency: Verify if the company has secured the additional funding required for the remainder of 1996 to avoid operational curtailment.
- Revenue Replacement: Assess the status of new business alliances intended to replace the lost $948,000 Sanofi Winthrop bSOD revenue.
- Debt Conversion: Confirm the timeline for the conversion of $766,000 in shareholder notes into Series C Preferred Stock, which would reduce the working capital deficit.
- Product Pipeline: Review the progress of the two lead therapeutics programs (glutathione peroxidase mimics and lipid soluble antioxidants) which are consuming significant R&D resources.